Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

T2 Biosystems1,500 enrolled

Overview

The purpose of this study is to validate clinical performance (i.e. estimated sensitivity and specificity) of the T2 Candida test on the T2 DX Instrument compared to blood culture results and/or known Candida positive status of prospectively collected and contrived (i.e. Candida-spiked) clinical specimens.

This study will prospectively collect and analyze whole blood T2 clinical research specimens and concomitant blood culture specimens from patients who have been referred for a blood culture per routine standard of care. Additional analysis of blinded, contrived (i.e. Candida spiked and un-spiked whole blood) specimens will be completed by study sites to augment the analysis of Candida positive blood specimens prospectively obtained from the study population. The clinical performance of the T2 Candida test on the T2 Dx Instrument will be evaluated by calculating the: * Estimated clinical specificity of the T2Candida test results compared to Candida negative blood culture results in prospectively collected specimens, and the * Estimated sensitivity of the T2 Candida test results compared to the known Candida positive status or Candida positive blood culture status of contrived specimens that have been spiked at clinically relevant concentrations of the target organisms and, where detected, to Candida positive blood culture results in prospectively collected clinical specimens.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Candidemia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 95 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them. 2. Subject has had a blood culture ordered, per routine standard of care. 3. Subject is between 18-95 years of age Exclusion Criteria: 1. Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study. 2. Subject has had previous specimens tested by the T2Candida assay with valid results. 3. Subject has had an anti-fungal drug administered through the same port or central line as is used to collect the clinical research specimens. 4. Treatment of subject with any novel drug compound within 30 days prior to the collection of T2 blood specimens. 5. T2 clinical specimen, Tube A contains \<3ml of blood.

Locations (8)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Georgia Regents University

Augusta, Georgia, United States

Henry Ford Health System

Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

Specificity

Estimated specificity of the T2Candida test will be examined by comparing T2Candida test results from prospectively collected T2 clinical specimens to blood culture results from specimens that are culture negative for Candida and which have been collected at the same time and from the same anatomical location as the T2 specimens.

Time frame: Up to 19 hours post blood collection

Sensitivity

Estimated sensitivity of the T2Candida test will be examined by comparing T2Candida test results to the known Candida positive status or Candida positive blood culture status of contrived specimens that have been spiked at clinically relevant concentrations of the target organisms and, where detected, to blood culture results from specimens that are culture positive for Candida and which have been collected at the same time and from the same anatomical location as the T2 specimens.

Time frame: Up to 19 hours post blood collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.